--- name: the-lancet-oncology description: Use when targeting The Lancet Oncology or deciding whether a clinical oncology manuscript fits this venue. Encodes the journal's fit, framing, method-and-evidence bar, house style, official-submission re-check, and desk-reject heuristics. --- # The Lancet Oncology (the-lancet-oncology) ## Journal positioning The Lancet Oncology is a flagship specialty title in the Lancet family and one of the world's most prestigious clinical oncology journals, published by Elsevier. It publishes practice-changing cancer clinical trials, oncology policy, cancer epidemiology, and translational cancer research that is directly relevant to the clinical management of cancer at a global level. The journal maintains the Lancet family's editorial standards: rigorous trial registration, CONSORT compliance, equity and global-health consciousness, and a bias toward findings that shift oncology practice or inform cancer policy. Studies that are methodologically sound but incremental—small improvements in surrogate endpoints, single-arm studies without historical context, or descriptive epidemiology without actionable implications—are unlikely to succeed here. This skill is a **fit / venue-selection / re-framing** tool. It does not replace the journal's current official submission guidelines. Before submitting, re-check the live author instructions on the Lancet/Elsevier site or submission system. ## When to trigger - The author names The Lancet Oncology as the target venue for a phase III cancer trial, cancer epidemiology analysis, or oncology-policy paper. - A cancer clinical trial has results that could change standard of care across a patient population at international scale. - A cancer-burden or cancer-control analysis has policy implications for global or regional oncology systems. - The author needs The Lancet Oncology's desk-reject risks and credible alternatives before submitting. ## Scope & topic fit - Phase III and large phase II randomised controlled trials in any cancer type with patient-centred primary endpoints (overall survival, progression-free survival with mature data, quality of life). - First-in-class drug approvals, definitive biomarker-selected trial results, and adaptive or platform trial designs with practice-changing results. - Cancer epidemiology: global cancer burden, incidence and mortality trends, population-level cancer screening effectiveness. - Oncology policy and health-systems research: cancer control in LMICs, access to cancer medicines, treatment guidelines at population scale. - Precision oncology: biomarker-defined patient populations, molecular tumour boards, genomic stratification with clinical outcome data. - Translational findings from trials: correlative biomarker data within a practice-changing clinical trial, not standalone discovery. ## Method & evidence bar - Randomised trials must be pre-registered (ClinicalTrials.gov or ISRCTN or equivalent), CONSORT-compliant in full including a CONSORT flow diagram, and powered for a clinically meaningful primary endpoint. - Phase II single-arm studies are published only when they establish a new standard for a rare tumour type or a breakthrough clinical signal with regulatory-approval implication. - Systematic reviews and meta-analyses of cancer trials require PRISMA adherence, PROSPERO registration, and GRADE evidence profiling. - Survival analyses must report hazard ratios with confidence intervals, Kaplan-Meier curves with patients-at-risk tables, and median follow-up duration. - Biomarker and molecular analyses embedded within trials must follow pre-specified analysis plans; exploratory correlative data should be clearly labelled as hypothesis-generating. - Ethics approval, independent data-safety monitoring board (for phase III trials), and informed consent are mandatory; ICMJE authorship and competing-interests disclosure are required. ## Structure & house style - The Lancet Oncology uses a structured abstract (background, methods, findings, interpretation) followed by a funding statement; the Interpretation sentence must state the clinical implication directly. - An "Added value of this study" summary panel (what is already known, what this study adds) is required; it must be specific to this trial's contribution—generic claims are rejected. - Opening paragraphs should establish the unmet clinical need and the current standard of care that this study addresses or surpasses. - Kaplan-Meier figures are standard; ensure they include patients-at-risk tables; colour-blind-accessible palettes are expected. - Statistical reporting must include absolute differences in survival rates at landmark timepoints in addition to hazard ratios; minimise sole reliance on relative-effect measures. - Ancillary oncology-specific content: subgroup forest plots must note that subgroup analyses are exploratory unless pre-specified. ## Official-submission checklist - Before giving submission-ready advice, read `../../resources/source-basis.md` and `../../resources/official-source-map.md`; start from the official source anchors for this journal family, then cite the current journal-specific page you checked. - Search the live site for "The Lancet Oncology information for authors" and follow the current Elsevier/Lancet version. - Re-check article type, current word/abstract/figure limits, and the "Added value" panel format. - Confirm trial registration number, ethics approval reference, independent data-safety monitoring board statement (phase III), and informed consent are documented. - Submit CONSORT checklist (or PRISMA for reviews) as a supplementary file with page-number citations. - Re-check data-sharing statement: what IPD or summary data will be shared, when, via which platform, and under what access conditions. - Re-check competing-interests declaration, funding disclosure (industry vs. academic funding independence), ICMJE author-contribution statement, and AI-use disclosure. - Re-check open-access/APC and licensing options; preprint policy. - If the live official instructions conflict with this skill, the official instructions win. ## Pre-submission self-check - [ ] One sentence stating which current standard-of-care this study supersedes or complements, and for which patient population. - [ ] The CONSORT flow diagram is prepared; patients at risk are shown in survival curves; hazard ratios and landmark survival rates are both reported. - [ ] The "Added value" panel is specific: what existing evidence was incomplete and what this study conclusively establishes. - [ ] Biomarker or subgroup analyses are clearly labelled as pre-specified or exploratory. - [ ] Trial registration, ethics, and data-sharing statement are complete. - [ ] All competing interests (especially industry support) are fully declared with clear statement of sponsor role in design, analysis, and publication. ## Common desk-reject triggers - Phase II single-arm trial in a common tumour type without a compelling unmet-need or breakthrough-designation rationale. - CONSORT flow diagram missing; primary endpoint differs from the registered endpoint without transparent amendment explanation. - Survival analyses without patients-at-risk tables or with immature follow-up that prevents meaningful interpretation. - Competing-interests disclosure that is incomplete or where the sponsor conducted the primary statistical analysis with no independent verification. - "Added value" panel that is generic or repeats the abstract rather than specifying what this study adds relative to existing evidence. - Biomarker or translational paper without a clinical trial anchor—purely preclinical or discovery studies belong in disease-biology journals. ## Re-routing decision - Same trial but more broadly generalised to all medicine beyond oncology → `the-lancet`. - ASCO-sponsored or US-focused oncology trial seeking society-journal publication → `journal-of-clinical-oncology`. - Mechanistic cancer-biology study underlying the clinical finding → `cancer-cell` or `nature-medicine`. - Phase I/II with strong translational mechanism → `nature-medicine` or `cancer-discovery`. - Rare haematological malignancy with mechanistic depth → `blood`. ## Output format ```text [Fit] High / Medium / Low (one-line reason) [Target] The Lancet Oncology [Topic tags] <2–3 closest topics> [Method/evidence] [Top risk] [Official items to re-check]
[Re-route suggestion] ```